Description
3ml of bacteriostatic water included
GLOW Blend (70 mg total peptide content)
Label composition:
10 mg BPC-157 + 10 mg TB-500 + 50 mg GHK-Cu
Overview:
This blend combines three investigational peptides commonly studied for their
potential roles in tissue repair, regeneration, and extracellular matrix support.
The formulation appears designed to target complementary biological
pathways involved in healing and skin-related research models.
Component Breakdown & Research Context
BPC-157 (10 mg)
Research Focus:
- Tendon and ligament repair (primarily animal models)
- Gastrointestinal mucosal healing
- Angiogenesis modulation
- Nitric oxide system interaction
Most available evidence comes from preclinical studies. Human clinical data
remain limited.
TB-500 (10 mg)
(Synthetic fragment of Thymosin Beta-4)
Research Focus:
- Cell migration and actin regulation
- Tissue remodeling
- Angiogenesis support
- Anti-inflammatory signaling
Preclinical research suggests a role in wound healing and muscle repair.
Robust
large-scale human trials are lacking.
GHK-Cu (50 mg)
(Copper tripeptide complex)
Research Focus:
- Collagen and elastin synthesis
- Extracellular matrix remodeling
- Gene expression modulation related to repair
- Anti-inflammatory and antioxidant effects
- Dermatological and cosmetic research
Among the three components, GHK-Cu has comparatively more documentation
in topical cosmetic research.
Theoretical Rationale for Combination
In research settings, combining these peptides may be intended to:
- Support angiogenesis and tissue perfusion (BPC-157, TB-500)
- Promote extracellular matrix remodeling (GHK-Cu)
- Modulate inflammatory pathways
- Enhance regenerative signaling cascades
However, there are no large-scale clinical trials evaluating this specific
combination as a standardized therapeutic formulation.
Evidence & Regulatory Status
- All three components are considered investigational in most regions.
- The combination product itself has not undergone formal regulatory approval processes.
- Long-term safety and efficacy data for combined systemic use are limited.
- Products labeled “for research use only” are not equivalent to approved pharmaceutical products.
FOR RESEARCH USE ONLY
